Affiliation:
1. Department of Infectious Diseases and Imperial Fungal Science Network, Imperial College London, London
2. Manchester Fungal Infection Group, University of Manchester, Manchester, UK
Abstract
Purpose of review
Chronic pulmonary aspergillosis is a major global infection in individuals with preexisting structural lung diseases and those with immunodeficiencies, in particular cytokine defects. Current treatment options are confined to just three drug classes, the triazoles, the echinocandins and amphotericin B. However, antifungal resistance is rapidly emerging for the triazoles, the only available oral therapy for this chronic condition.
Recent findings
Fortunately, there are now a number of novel antifungals in the development pipeline, mostly now in Phase 3 studies, with a potential for the treatment of chronic pulmonary aspergillosis. However, almost all current randomized triazoles of novel antifungals are primarily undertaken in patients with invasive candidiasis or invasive mould infections. Given the poor outcomes from treatment with antifungals in chronic pulmonary aspergillosis, in part associated with triazole resistance, we urgently need clinical trials of novel agents either as monotherapy or in combination for this disease. In addition, there is an emerging understanding of the role of immunotherapies for the treatment of chronic pulmonary aspergillosis, especially in the context of cytokine defects. Therefore, better understanding of the role of adjunctive immunotherapies such as interferon-gamma is also required.
Summary
In this review, we give an overview of current management of chronic pulmonary aspergillosis, and novel antifungals and immunotherapies for the future.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Microbiology (medical)
Reference34 articles.
1. Chronic pulmonary aspergillosis is common among patients with presumed tuberculosis relapse in Ghana;Ocansey;Med Mycol,2022
2. Clinical features, diagnostic test performance, and prognosis in different subtypes of chronic pulmonary aspergillosis;Zhong;Front Med (Lausanne),2022
3. Defective interferon-gamma production is common in chronic pulmonary aspergillosis;Colombo;J Infect Dis,2022
4. Imaging spectrum in chronic pulmonary aspergillosis;Garg;Am J Trop Med Hyg,2023
5. Identification of distinct immunophenotypes in chronic pulmonary aspergillosis using cluster analysis;Sehgal;Mycoses,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献